Health Care • Biotechnology: Pharmaceutical Preparations
$2.70 ▲ +0.14
(+5.47%)
MKT CAP: $36.5M • VOL: 44.4K
52W L $1 52W H $20
ROARABLE / RQD
D- • 42/100
PIOTROSKI
1 / 9
EDSA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.9M | -$7.0M | -$9.2M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$7.2M | -$6.2M | -$8.4M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.3M | -$4.9M | -$6.6M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$7.3M | -$4.9M | -$6.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $12.1M | $1.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $14.0M | $2.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EDSA.